173 related articles for article (PubMed ID: 37006282)
1. Pan-Cancer analysis and experimental validation identify the oncogenic nature of ESPL1: Potential therapeutic target in colorectal cancer.
Zhong Y; Zheng C; Zhang W; Wu H; Wang M; Zhang Q; Feng H; Wang G
Front Immunol; 2023; 14():1138077. PubMed ID: 37006282
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of ESPL1 is associated with poor prognostic outcomes in endometrial cancer.
Yang Y; Sheng Y; Zheng J; Ma A; Chen S; Lin J; Yang X; Liang Y; Zhang Y; Zheng X
Biomarkers; 2024 Jun; 29(4):185-193. PubMed ID: 38568742
[TBL] [Abstract][Full Text] [Related]
3. Biology and insights into the role of cohesin protease separase in human malignancies.
Zhang N; Pati D
Biol Rev Camb Philos Soc; 2017 Nov; 92(4):2070-2083. PubMed ID: 28177203
[TBL] [Abstract][Full Text] [Related]
4. High Rate of Detection of Human ESPL1-HBV S Fusion Gene in Patients With HBV-related Liver Cancer: A Chinese Case-Control Study.
Hu B; Huang W; Wang R; Zang W; Su M; Li H; Wang H; Cao B; Deng D; Li QQ; Jiang J
Anticancer Res; 2020 Jan; 40(1):245-252. PubMed ID: 31892573
[TBL] [Abstract][Full Text] [Related]
5. Extra Spindle Pole Bodies-Like 1 Serves as a Prognostic Biomarker and Promotes Lung Adenocarcinoma Metastasis.
Nie Z; Pu T; Han Z; Wang C; Pan C; Li P; Ma X; Yao Y; Zhao Y; Wang C; Jiang X; Ding J
Front Oncol; 2022; 12():930647. PubMed ID: 35814478
[TBL] [Abstract][Full Text] [Related]
6. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
7. Separase loss of function cooperates with the loss of p53 in the initiation and progression of T- and B-cell lymphoma, leukemia and aneuploidy in mice.
Mukherjee M; Ge G; Zhang N; Huang E; Nakamura LV; Minor M; Fofanov V; Rao PH; Herron A; Pati D
PLoS One; 2011; 6(7):e22167. PubMed ID: 21799785
[TBL] [Abstract][Full Text] [Related]
8. ESPL1 Is a Novel Prognostic Biomarker Associated With the Malignant Features of Glioma.
Liu Z; Lian X; Zhang X; Zhu Y; Zhang W; Wang J; Wang H; Liu B; Ren Z; Zhang M; Liu M; Gao Y
Front Genet; 2021; 12():666106. PubMed ID: 34512713
[TBL] [Abstract][Full Text] [Related]
9. ESPL1 is Elevated in Hepatocellular Carcinoma and Predicts Prognosis.
Song R; Huang J; Yang C; Li Y; Zhan G; Xiang B
Int J Gen Med; 2022; 15():8381-8398. PubMed ID: 36465268
[TBL] [Abstract][Full Text] [Related]
10. TTK, CDC25A, and ESPL1 as Prognostic Biomarkers for Endometrial Cancer.
Yang Q; Yu B; Sun J
Biomed Res Int; 2020; 2020():4625123. PubMed ID: 33282948
[TBL] [Abstract][Full Text] [Related]
11. Let-7c-5p Restrains Cell Growth and Induces Apoptosis of Lung Adenocarcinoma Cells via Targeting ESPL1.
Liu X; Zeng W; Zheng D; Tang M; Zhou W
Mol Biotechnol; 2022 Dec; 64(12):1367-1375. PubMed ID: 35639278
[TBL] [Abstract][Full Text] [Related]
12. MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ERĪ±)-positive mammary adenocarcinomas.
Mukherjee M; Ge G; Zhang N; Edwards DG; Sumazin P; Sharan SK; Rao PH; Medina D; Pati D
Oncogene; 2014 Nov; 33(48):5511-5522. PubMed ID: 24276237
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
Front Immunol; 2022; 13():994828. PubMed ID: 36405728
[TBL] [Abstract][Full Text] [Related]
14. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study.
Wang R; Zang W; Hu B; Deng D; Ling X; Zhou H; Su M; Jiang J
Technol Cancer Res Treat; 2020; 19():1533033820980785. PubMed ID: 33308056
[TBL] [Abstract][Full Text] [Related]
15. Association of the Timeless Gene with Prognosis and Clinical Characteristics of Human Lung Cancer.
Ye J; Chen J; Wang J; Xia Z; Jia Y
Diagnostics (Basel); 2022 Nov; 12(11):. PubMed ID: 36359523
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide CRISPR screen identifies ESPL1 limits the response of gastric cancer cells to apatinib.
Zhang B; Chen Y; Chen X; Ren Z; Xiang H; Mao L; Zhu G
Cancer Cell Int; 2024 Feb; 24(1):83. PubMed ID: 38402402
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis: SPAG5 is an immunological and prognostic biomarker for multiple cancers.
Gao X; Bu H; Gao X; Wang Y; Wang L; Zhang Z
FASEB J; 2023 Oct; 37(10):e23159. PubMed ID: 37650687
[TBL] [Abstract][Full Text] [Related]
18. Molecular Characteristics, Oncogenic Roles, and Relevant Immune and Pharmacogenomic Features of EVA1B in Colorectal Cancer.
Ma B; Wang K; Liang Y; Meng Q; Li Y
Front Immunol; 2022; 13():809837. PubMed ID: 35250982
[TBL] [Abstract][Full Text] [Related]
19. Identification of aberrantly methylated differentially expressed genes and associated pathways in endometrial cancer using integrated bioinformatic analysis.
Liu J; Wan Y; Li S; Qiu H; Jiang Y; Ma X; Zhou S; Cheng W
Cancer Med; 2020 May; 9(10):3522-3536. PubMed ID: 32170852
[TBL] [Abstract][Full Text] [Related]
20. ITGBL1 promotes migration, invasion and predicts a poor prognosis in colorectal cancer.
Qiu X; Feng JR; Qiu J; Liu L; Xie Y; Zhang YP; Liu J; Zhao Q
Biomed Pharmacother; 2018 Aug; 104():172-180. PubMed ID: 29772438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
